Nonmyeloablative allogeneic stem cell transplants are currently being evaluated in patients with haematological malignancies considered poor candidates for standard allogeneic transplantation because of advanced age or other concurrent medical conditions. 1, 2 The rationale for nonmyeloablative transplants relies on previous observations that adoptive transfer of allo-reactive donor Tlymphocytes may eradicate haematological diseases not being cured by the previous allogeneic stem cell transplantation. [3] [4] [5] On the other hand, patients with haematologic diseases who are nonresponsive to conventional chemoradiotherapy may also be candidates. It is unlikely that these patients will benefit from the high-dose chemoradiotherapy, given with myeloablative regimens for standard stem cell transplantation, but they may respond to the alloreactive donor T cells. The less intensive conditioning regimen is only necessary for engraftment of the donor stem cells.
A 20-year-old female patient presented in February 2001 with a cutaneous CD30-negative large T-cell lymphoma. The disease was limited to the skin and field radiotherapy was started. However, during radiotherapy new lesions appeared. The skin tumours were progressive during treatment with four courses of cyclophosphamide, adriamycin, oncovin and prednisone, two courses of high-dose methotrexate (2000 mg, i.v., with leucovorin rescue) and two courses of vepesid (200 mg, i.v.). Finally, in December 2001 more than 100 ulcerating nodules and plaques all over her body were observed (Figure 1a) . Her father was found to be HLA compatible with one locus mismatch (DR14 vs DR13 in the patient). She agreed to undergo nonmyeloablative peripheral stem cell transplantation. After 4 days of anti-T-cell globulin (2 mg/kg body weight/day), 3 days of fludarabin (30 mg/kg/day) and low-dose total body irradiation (2 Gy), she received non-T-cell depleted peripheral blood stem cell graft from her father. During the first 4 weeks after transplantation, the disease was still progressive and graft-versus-host disease was not observed. Therefore, the immunosuppressive drugs (mycophenolate mofetil and cyclosporine) were tapered and finally stopped. At 6 weeks after the transplant, fluorescent in situ hybridisation with a probe against the Y chromosome revealed Y-positive lymphocytes (derived from her father) surrounding the malignant Y-negative T cells in the skin tumour (Figure 2 ). In the following weeks, all tumours gradually disappeared Photographs shown with permission of the patient.
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www.nature.com/bmt and after 6 months, no signs of cutaneous lymphoma could be observed anymore. At 1 year after transplantation, she is in good health and able to perform normal daily activities. Severe scarring and postinflammatory hyperpigmentation remains, but is gradually improving (Figure 1b) .
Complete remission of this aggressive, resistant CD30-negative large cutaneous T-cell lymphoma was most likely because of graft-versus lymphoma induced by the nonmyeloablative transplant. The infiltration of the skin tumours by donor lymphocytes underscores the graft-versus-lymphoma mechanism. Cutaneous CD30-negative large T-cell lymphoma is a rare disease with aggressive behaviour. 6, 7 The median age is around 50 years, significantly younger compared to the other cutaneous lymphomas. 6 The 5-year survival rate is low, around 15-20%. 6, 7 In general, localised cutaneous T-cell lymphomas are best treated with radiation therapy. 6 Lymphomas progressive after radiotherapy and patients with multiple localisations should be treated with chemotherapy. This case shows that a nonmyeloablative stem cell transplant may be an effective treatment for an otherwise incurable and very aggressive T-cell lymphoma of the skin.
